A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2004
12/22/2004	EP1487491A2 Novel of cytokine inhibitors
12/22/2004	EP1487488A1 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
12/22/2004	EP1487486A2 Imidazoquinolineamines as adjuvants in hiv dna vaccination
12/22/2004	EP1487483A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
12/22/2004	EP1487482A2 Dna vaccine against proliferating endothelial cells and methods of use thereof.
12/22/2004	EP1487480A2 Fusion molecules and methods for treatment of immune diseases
12/22/2004	EP1487463A2 Local production and/or delivery of anti-cancer agents by stromal cell precursors
12/22/2004	EP1487412A1 Chemosensitizing with liposomes containing oligonucleotides
12/22/2004	EP1487274A2 Tissue engineering
12/22/2004	EP1333719A4 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
12/22/2004	EP1175430A4 Antisense-oligos with better stability and antisense effect
12/22/2004	EP0929536B1 Piperazine based cytofectins
12/22/2004	EP0906110B1 Dna vaccine formulations
12/22/2004	EP0832271B1 Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
12/22/2004	EP0832253B9 Nucleic acid respiratory syncytial virus vaccines
12/22/2004	EP0786005B1 Compositions for treatment of coronary artery diseases using gene therapy.
12/22/2004	CN1556221A Use of IC 53 gene and its related product in diagnosing and treating colon cancer and reagent box for diagnosing colon canter
12/22/2004	CN1556220A Antigen polypeptide of IC53 gene product, use of automatibody in diagonosis and treating of arrhythmia cardimyopathy and reagent kit containing the polypeptide
12/22/2004	CN1555890A Anticancer medicine containing CARF gene and its related product and its use
12/22/2004	CN1180847C Ejecting pneumatic gene gun
12/21/2004	US6833348 Inhibiting apoptosis mediated by CD3 T-cell receptor or Fas/Fas-L systems; stimulating lymphocyte activity
12/21/2004	US6833248 Polypeptides; culture product
12/21/2004	US6833243 For diagnosis of psychosis/schizophrenia via detection of mutant allele
12/21/2004	CA2140649C Hybrid oligonucleotide phosphorothioates
12/16/2004	WO2004108945A2 Oligonucleotide modulation of cell adhesion
12/16/2004	WO2004108940A2 Viral genome vectors
12/16/2004	WO2004108939A2 Bav packaging regions and e1 transcriptional control regions
12/16/2004	WO2004108938A2 Peptide ligands of dendritic cells for nucleic acid vector targeting
12/16/2004	WO2004108921A1 Method of nucleic acid infusion
12/16/2004	WO2004108893A2 Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
12/16/2004	WO2004108840A2 Nucleotides for prevention and treatment of bacterial and fungal pathologies
12/16/2004	WO2004108760A2 Improved secretion of neublastin
12/16/2004	WO2004108167A1 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
12/16/2004	WO2004108166A1 Epas1 gene transfer to improve cell therapy
12/16/2004	WO2004108088A2 Methods and compositions for interferon therapy
12/16/2004	WO2004108087A2 Gene delivery to organs
12/16/2004	WO2004108072A2 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/16/2004	WO2004094588A3 Postnatal stem cells and uses thereof
12/16/2004	WO2004081198A3 Methods for modulating angiogenesis with apelin compositions
12/16/2004	WO2004078940A3 USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
12/16/2004	WO2004061423A3 Compositions and methods for diagnosing and treating colon cancers
12/16/2004	WO2004052297A3 TREATMENT OF HSV-RELATED PATHOLOGIES USING ssDNA
12/16/2004	WO2004009790A3 Metastatic colon cancer specific promoter and uses thereof
12/16/2004	WO2003092582B1 Chimeric ebola virus envelopes and uses therefor
12/16/2004	WO2003059268A3 A novel germ cell-specific contraceptive target
12/16/2004	WO2003054152A3 Novel nucleic acids and polypeptides
12/16/2004	WO2003050245A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/16/2004	WO2002070665A8 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
12/16/2004	US20040254349 Mycobacterial antigens expressed under low oxygen tension
12/16/2004	US20040254340 Expression vetor comprising cell surface glycoprotein for use in prevention and treatment of neurodegenerative disorders; memory enhancement and learning
12/16/2004	US20040254140 Method for selective inactivation of viral replication
12/16/2004	US20040254138 Vectors containing genomic Dna, Rna encoding replacement gene; bone disordwers; vision defects; antidepressants; anticancer agents
12/16/2004	US20040254137 Nucleotide sequences; for therapy of bone disorders, chondrondysplasis; biodrug; activation caspase signaling cascade
12/16/2004	US20040254135 Administering enzyme inhibitor; moderate metabolism
12/16/2004	US20040254134 Modulating heart cells; administering polynucleotide; adjust contraction
12/16/2004	US20040254132 Ovary-specific genes and proteins
12/16/2004	US20040253731 Solution comprising surfactant, hydrophobic phase and hydrophilic phase comprising plurality of microcapsules containing functional in vitro eukaryotic expression system for transfer of heterologous into cells
12/16/2004	US20040253730 Identifying modulators which induce apoptosis and activate cell cycle checkpoint systems; for use in treatment and prevention of cell proliferative disorders
12/16/2004	US20040253723 Modulation of growth hormone receptor expression and insulin-like growth factor expression
12/16/2004	US20040253720 Use of the cd24 marker gene for the selection of keratinocyte stem cells transformed by exogenous sequences
12/16/2004	US20040253698 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
12/16/2004	US20040253685 eNOS mutations useful for gene therapy and therapeutic screening
12/16/2004	US20040253684 Nucleotide sequences coding mambrane associated guanylate kinase for use in treatment and prevention of nervous system, blood, sleep and behavioral disorders
12/16/2004	US20040253683 Cryptopain compositions for prophylaxis, treatment, diagnosis and detection of cryptosporidium species
12/16/2004	US20040253681 Mitogenic oxygenase regulators
12/16/2004	US20040253610 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders
12/16/2004	US20040253602 Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
12/16/2004	US20040253581 Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins
12/16/2004	US20040253316 Production scale method of forming microparticles
12/16/2004	US20040253272 Process for producing inactivated virus envelopes
12/16/2004	US20040253270 Nucleic acid encoding infectious, nonpathogenic porcine circovirus type-1(PCV1), which contains immunogenic open reading frame gene of pathogenic PCV2 in place of an ORF gene of PCV1 nucleic acid molecule; means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome
12/16/2004	US20040253245 Modulating an immune response by administering a modulator of Notch intracellular domain protease activity, including modulators of presenilin and presenilin-dependent gamma secretase activity; immunotherapy; treatment of Alzheimer's disease
12/16/2004	US20040253239 nucleotide sequences that code angiogenic factor antagonists and vascular endothelial structure regulators, used for prevention of angoigenesis or cancer; gene therapy
12/16/2004	US20040253231 monoclonal or polyclonal antibodies having specific reactivity with adenosine triphosphate binding domains, caspase recruitment domains and triosephosphate isomerase domain peptides, used for modulation of apoptosis
12/16/2004	US20040253218 Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
12/16/2004	US20040253216 Activated checkpoint therapy and methods of use thereof
12/16/2004	US20040253215 Methods and compositions for treating disorders
12/16/2004	US20040253214 fusing cells; nucleic acid vector comprises a nucleotide sequence encoding a measles virus F glycoprotein and a nucleotide sequence encoding a chimeric measles virus H glycoprotein; nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface
12/16/2004	US20040253212 Medicament injection kit and medicament injection method
12/16/2004	US20040253211 analyzing the expression of claudin-3, claudin-4 and claudin-9; if these genes are under-expressed, the transformed/cancerous cell is a metastatic cell; nucleic acid is transfected into the cancerous cell
12/16/2004	US20040253210 replication-defective adenovirus type 7 that expresses one or more HIV polypeptides for use in stimulating an immune response to HIV-1; adenovirus serotype 7 cosmid vector; gene therapy
12/16/2004	CA2536472A1 Epas1 gene transfer to improve cell therapy
12/16/2004	CA2528136A1 Transfection agents
12/16/2004	CA2528131A1 Nucleotides for prevention and treatment of bacterial and fungal pathologies
12/16/2004	CA2527914A1 Improved secretion of neublastin
12/16/2004	CA2527658A1 Methods and compositions for interferon therapy
12/16/2004	CA2526792A1 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
12/16/2004	CA2526482A1 Peptide ligands of dendritic cells for nucleic acid vector targeting
12/16/2004	CA2525401A1 Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
12/16/2004	CA2524229A1 Canine ghrh gene, polypeptides and methods of use
12/16/2004	CA2521682A1 Delivery of immune response modifier compounds using metal-containing particulate support materials
12/15/2004	EP1486567A1 Improved adeno-associated virus (AAV) vector for gene therapy
12/15/2004	EP1486565A1 Combination PDGF, KGF, IGF, and IGFBP for wound healing
12/15/2004	EP1486505A1 Angiotensin derivatives
12/15/2004	EP1486504A1 Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof
12/15/2004	EP1485488A2 Recombinant negative strand virus rna expression systems and vaccines
12/15/2004	EP1485487A2 Cartilage regeneration using chondrocyte and tgf-beta
12/15/2004	EP1485480A2 Cd40 splice variants, method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
12/15/2004	EP1485475A1 Hybrid and single chain meganucleases and use thereof
12/15/2004	EP1485410A1 Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases

1 ... 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 ... 870